Related Experiment Videos
Immunoregulatory T cells in tumor immunity
Masaki Terabe1, Jay A Berzofsky
1Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892-1578, USA. terabe@mail.nih.gov
Current Opinion in Immunology
|March 17, 2004
Summary
Immunoregulatory T cells suppress anti-tumor immunity, hindering cancer vaccines. Blocking these cells in mice and humans may enhance cancer immunosurveillance and immunotherapy effectiveness.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Cancer immune evasion involves immunosuppression by regulatory T cells.
- CD4(+)CD25(+) T cells and NKT cells are key players in this immunosuppression.
- Understanding these mechanisms is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate the role of immunoregulatory T cells in cancer immune evasion.
- To explore the potential of targeting these cells for cancer immunotherapy.
Main Methods:
- Analysis of CD4(+)CD25(+) T cells and NKT cells in mouse models and human cancer patients.
- Studies involving the removal or blockade of immunoregulatory T cell activity.
Main Results:
- Mouse studies demonstrated that depleting regulatory T cells or blocking their pathways enhances anti-tumor immunity.
- These interventions improved responses to cancer vaccines in preclinical models.
- Similar T-cell populations in human patients suggest a comparable role in cancer immunosuppression.
Conclusions:
- Immunoregulatory T cells are significant contributors to cancer immune evasion.
- Targeting these regulatory T cells presents a promising strategy for improving cancer vaccine efficacy and immunotherapy outcomes.